Rise Advisors’s Denali Therapeutics DNLI Stock Holding History

Rise Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-74	Closed	-$1.07K	–	470
2025 Q3	$1.07K	Hold	74	–	–	﹤0.01%	1272
2025 Q2	$1.03K	Buy	+74	New	+$1.04K	﹤0.01%	1277

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Rise Advisors's DNLI Position: Q4 2025 in Review

Rise Advisors sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 74 shares — an estimated $1.07K sold.

Rise Advisors first reported a position in DNLI in Q2 2025 and held it in 2 quarters. The position peaked at $1.07K in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Rise Advisors reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 74 Denali Therapeutics shares in Q4 2025, an estimated $1.07K.
Rise Advisors first reported a position in Denali Therapeutics in Q2 2025 and held it in 2 quarters.
Rise Advisors's Denali Therapeutics position peaked at $1.07K in Q3 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.